<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998762</url>
  </required_header>
  <id_info>
    <org_study_id>15-9055-AE</org_study_id>
    <nct_id>NCT02998762</nct_id>
  </id_info>
  <brief_title>Long-Term Follow Up Study</brief_title>
  <acronym>CAN-BIND LTFU</acronym>
  <official_title>CAN-BIND (Canadian Biomarker Integration Network for Depression): Long-Term Follow Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kennedy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LTFU study will conduct a naturalistic follow up of the well characterized CAN-BIND study
      population of patients every six months and continuing over a five-year period. This will
      provide information on the longitudinal progress in mood, functioning, and quality of life of
      the CAN-BIND sample with a view towards long-term outcome and treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a long-term follow up study of the 'Canadian Biomarker Integration Network in
      Depression' (CAN-BIND) study. The CAN-BIND study examines biological markers of
      antidepressant treatment response. The examined biomarkers included clinical, imaging, and
      genetic components. The Long Term Follow up (LTFU) study will continue to follow the patients
      in this study each six months over a five year period. By doing so, a comprehensive clinical
      outcome data on a well characterized cohort of depressed patients will be obtained.

      The research team will conduct a naturalistic study of CAN-BIND participants and will monitor
      the longitudinal progress in mood, functioning, and quality of life, with a view towards
      advising future treatment options. Each patient completing CAN-BIND will be asked to
      participate in the LTFU study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 3, 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg 1979) scores from CAN-BIND baseline</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>Clinical response (equal to or greater than 50% reduction in MADRS scores from CAN-BIND baseline); Relapse is determined if the MADRS score is greater than or equal to 22 or there is suicidal ideation with intent, or suicidal behaviour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Interval Follow-up Evaluation (LIFE) (Keller et al., 1978)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The LIFE is a clinician-rated interview that provides a structure for collecting and coding data on the longitudinal course of psychopathology. It allows for precise dating of onset and offset of symptoms (including sub-syndromal symptoms) and ranks severity on a week by week basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Events and Difficulties Schedule (LEDS) (Brown &amp; Harris, 1978)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The LEDS is a semi-structured interview that collects detailed contextual information regarding acute stressful life events and chronic difficulties in several domains.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quick Inventory Depressive Symptomatology-Self Report (QIDS-SR) (Rush et al., 2003)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The QIDS-SR is a 16 item scale used to assess the severity of depressive illness derived from the 30-item Inventory of Depressive Symptomatology (IDS). The scale includes questions on mood, sleep and level of interest, and takes 5-10 minutes to complete.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Endicott et al., 1993)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>This 16-item questionnaire contains questions about your general life satisfaction on aspects such as physical health, leisure time and overall sense of well-being. Each item is scored on a 5-point scale (very poor to very good); higher scores indicate greater satisfaction and enjoyment. It takes 5 minutes to complete.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sheehan Disability Scale - Visual Analog Scale (SDS-VAS) (Sheehan et al., 1996)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The SDS-VAS is a self-rated questionnaire that assesses functional disability and impairment due to psychiatric symptoms. The SDS-VAS consists of three functional impairment items and two items related to productivity losses due to the symptoms and impairment. Impairment is evaluated with the 10-point self-rated social life and family life/home responsibilities subscales of the Sheehan Disability Scale (0, none; 1-3, mild; 4-6, moderate; 7-9, marked; 10, extreme). Significant impairment for each subscale was defined by a rating of 7 or higher.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Dimensional Anhedonia Rating Scale (DARS) (Rizvi et al., 2015)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The DARS is a new measure of anhedonia developed to address the limitations of the existing scales. It extends the concept of anhedonia to assess desire, motivation, effort and consummatory pleasure across four domains: pastimes/hobbies, food/drink, social activities and sensory experiences. Individuals are asked to list their own examples within each domain and respond to standardized questions on a Likert scale according to how they are feeling &quot;right now&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>World Health Organization Quality of Life Short Version (WHOQOL-BREF) (Orley &amp; Kuyken, 1994)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The WHOQOL-BREF is a 26-item self-rated questionnaire that assesses perceived quality of life across four domains. The domains of health assessed include physical health, psychological health, social relationships and environment. Domain scores and global scores can be generated. The questions are related to aspects of the patient's life in the last four weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief Symptom Inventory (BSI-53) (Derogatis et al., 1993)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The BSI-53 is a 53-item self-rated questionnaire that assesses depression across nine symptom dimensions. The nine dimensions are somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism. The number and intensity of symptomatology is given by three indices, the Global Severity Index, Positive Symptom Distress Index and Positive Symptom Total (PST). Each item is ranked on a 5-point scale from 0 (not at all) to 4 (extremely), and rankings represent intensity of distress over the past week.</description>
  </other_outcome>
  <other_outcome>
    <measure>Generalized Anxiety Disorder 7-item (GAD-7) (Spitzer et al., 2006)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The GAD-7 is a 7-item self-rated questionnaire with good reliability and validity for assessing generalized anxiety disorder and its severity over the past two weeks. Items are ranked on a 4-point scale from 0 (not at all sure) to 3 (nearly every day), providing a total severity score from 0 to 21.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI) (Buysse at al., 1989)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The PSQI is a self-rated questionnaire specifically designed to measure sleep quality. The questionnaire includes questions on sleep duration, sleep disturbance, sleep latency, day dysfunction due to sleepiness, sleep efficiency, overall sleep quality and need for medication to sleep. This questionnaire takes less than 5 minutes to complete.</description>
  </other_outcome>
  <other_outcome>
    <measure>Copenhagen Burnout Inventory (CBI) (Kristensen et al., 2005)</measure>
    <time_frame>Every six months up to Year 5</time_frame>
    <description>The CBI consists of three scales measuring personal burnout, work-related burnout, and client-related burnout, for use in different domains. Each subscale on the CBI is scored from a range of 0 to 100. Respondents who gained an average score of 50 or higher on each of the scales are deemed to have a positive response to the screen and to warrant further investigation by a mental health professional.</description>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Major Depressive Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Each patient completing the 16 weeks of CAN-BIND who have previously met DSM-IV-TR criteria
        for Major Depressive Episode (MDE) in MDD as determined by MINI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Each patient completing the 16 weeks of CAN-BIND who have previously met DSM-IV-TR
             criteria for Major Depressive Episode (MDE) in MDD as determined by MINI.

        Exclusion Criteria:

          -  Any Axis I diagnosis, other than MDD, that is considered the primary diagnosis.

          -  Bipolar I or Bipolar II diagnosis (lifetime), MDD with psychotic features (lifetime),
             schizophrenia or schizoaffective disorder.

          -  Presence of a significant Axis II diagnosis (borderline, antisocial).

          -  High suicidal risk, defined by clinician judgement.

          -  History of drug or alcohol use, with a severity of at least moderate or severe,
             according to DSM criteria, within the previous 6 months.

          -  Presence of significant neurologic disorder, head trauma, or other unstable medical
             conditions.

          -  Subject has any condition, for which in the opinion of the investigator, participation
             would not be in the interest of the subject (e.g. compromise the well-being) or that
             could prevent, limit, or confound the protocol-specified assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney H. Kennedy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shane McInerney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.canbind.ca</url>
    <description>CAN-BIND Study Website</description>
  </link>
  <reference>
    <citation>Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976-89.</citation>
    <PMID>22681173</PMID>
  </reference>
  <reference>
    <citation>Vaccarino AL, Evans KR, Kalali AH, Kennedy SH, Engelhardt N, Frey BN, Greist JH, Kobak KA, Lam RW, MacQueen G, Milev R, Placenza FM, Ravindran AV, Sheehan DV, Sills T, Williams JB. The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. Innov Clin Neurosci. 2016 Oct 1;13(9-10):20-31. eCollection 2016 Sep-Oct. Review.</citation>
    <PMID>27974997</PMID>
  </reference>
  <reference>
    <citation>Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feilotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen GM, McAndrews MP, Minuzzi L, MÃ¼ller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Kennedy SH; CAN-BIND Investigator Team. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry. 2016 Apr 16;16:105. doi: 10.1186/s12888-016-0785-x.</citation>
    <PMID>27084692</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Sidney Kennedy</investigator_full_name>
    <investigator_title>Senior Scientist, Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>major depression</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>biomarkers</keyword>
  <keyword>MDD</keyword>
  <keyword>long term follow up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This study is funded in part by the Ontario Brain Institute (OBI). Data collected from this study is entered into a research database called &quot;Brain-CODE&quot;, deployed at a High Performance Computer Virtual Lab (HPCVL). The HPCVL supports the regulatory-compliant (e.g., 21 CRF Part 11, HIPAA, PIPEDA) processes for securing privacy of healthcare data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

